Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 9, 2026, 12:11 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 97–120 of 5,227 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Control/Placebo group Clear all

Conditions: Facioscapulohumeral Muscular Dystrophy (FSHD)
Interventions: Losmapimod oral tablet, Placebo oral tablet; Drug
Lead sponsor: Fulcrum Therapeutics; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 12
States / cities: Irvine, California • Los Angeles, California • Gainesville, Florida + 9 more

Conditions: Bipolar Depression, Suicidal Ideas, Suicidal Ideation, Suicide, Attempted
Interventions: NRX-101 Oral Capsule, Lurasidone Oral Capsule, Ketamine Intravenous Infusion, Saline Solution Intravenous Infusion; Drug
Lead sponsor: NeuroRx, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 4
States / cities: Birmingham, Alabama • Fort Lauderdale, Florida • Charlotte, North Carolina + 1 more

Conditions: Acute Upper Respiratory Track Infection
Interventions: Guaifenesin, Placebo; Drug · Device
Lead sponsor: Reckitt Benckiser Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 1,179 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 24
States / cities: Mesa, Arizona • Carmichael, California • Fresno, California + 21 more

Conditions: Dry Needling, Shoulder Pain
Interventions: Dry Needling, Sham Dry Needling; Other
Lead sponsor: Texas Woman's University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Pain, Postoperative
Interventions: Intravenous Acetaminophen, Placebo; Drug · Other
Lead sponsor: Children's Hospital of Philadelphia; Other
Eligibility: 10 Years to 18 Years
Enrollment: 67 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2015
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Diabetes Mellitus, Type 2
Interventions: Placebo identical to BI10773 high dose, BI 10773, BI 10773 open label, Placebo identical to BI10773 low dose, Placebo identical to Sitagliptin 100mg, BI10773, Sitagliptin; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years and older
Enrollment: 986 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2010
U.S. locations: 27
States / cities: Mesa, Arizona • Phoenix, Arizona • Hot Springs, Arkansas + 23 more

Conditions: Myocardial Fibrosis, Hypertrophic Cardiomyopathy
Interventions: Spironolactone, Placebo; Drug
Lead sponsor: Tufts Medical Center; Other
Eligibility: 18 Years to 70 Years
Enrollment: 53 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2012
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Dravet Syndrome (DS)
Interventions: Soticlestat, Placebo; Drug
Lead sponsor: Takeda; Industry
Eligibility: 2 Years to 21 Years
Enrollment: 144 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 10
States / cities: Phoenix, Arizona • Los Angeles, California • San Francisco, California + 7 more

Conditions: Parkinson's Disease
Interventions: nicotine, placebo comparator; Drug · Other
Lead sponsor: Neuraltus Pharmaceuticals, Inc.; Industry
Eligibility: 30 Years to 83 Years
Enrollment: 65 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 12
States / cities: Phoenix, Arizona • Los Angelis, California • Oxnard, California + 9 more

Conditions: Depressive Disorder, Major
Interventions: Radafaxine; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 64 Years
Enrollment: 367 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2007
U.S. locations: 21
States / cities: Peoria, Arizona • Scottsdale, Arizona • Garden Grove, California + 18 more

Conditions: Premature Birth of Newborn, Enterocolitis, Necrotizing
Interventions: Ampicillin, Gentamicins, Placebo; Drug
Lead sponsor: University of Chicago; Other
Eligibility: Up to 6 Hours
Enrollment: 27 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2019
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Episodic Migraine
Interventions: Eptinezumab, Placebo; Drug
Lead sponsor: H. Lundbeck A/S; Industry
Eligibility: 6 Years to 17 Years
Enrollment: 315 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 15
States / cities: Stamford, Connecticut • Gulf Breeze, Florida • Hialeah, Florida + 12 more

Conditions: Sarcoidosis
Interventions: Placebo, Golimumab, Ustekinumab; Drug
Lead sponsor: Centocor, Inc.; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 173 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 24
States / cities: Birmingham, Alabama • Los Angeles, California • Denver, Colorado + 21 more

Conditions: Multiple Sclerosis
Interventions: Teriflunomide, Placebo; Drug
Lead sponsor: Genzyme, a Sanofi Company; Industry
Eligibility: 10 Years to 17 Years
Enrollment: 166 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2024
U.S. locations: 4
States / cities: Cullman, Alabama • Tampa, Florida • Boston, Massachusetts + 1 more

Conditions: Post-traumatic Stress Disorder, PTSD
Interventions: Placebo, Brexpiprazole; Drug
Lead sponsor: H. Lundbeck A/S; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 417 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 22
States / cities: Los Angeles, California • Riverside, California • San Diego, California + 17 more

Conditions: Cornelia de Lange Syndrome
Interventions: N-acetyl cysteine, Placebo; Drug · Other
Lead sponsor: Johns Hopkins University; Other
Eligibility: 13 Years to 35 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Moderate to Severe Atopic Hand and Foot Dermatitis
Interventions: dupilumab, Placebo; Drug
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 12 Years and older
Enrollment: 133 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 17
States / cities: Birmingham, Alabama • Redwood City, California • Washington D.C., District of Columbia + 14 more

Conditions: Congestive Heart Failure
Interventions: AC2592, placebo; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years and older
Enrollment: 61 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2006
U.S. locations: 29
States / cities: Beverly Hills, California • Mission Viejo, California • New Haven, Connecticut + 26 more

Conditions: Eosinophilic Esophagitis (EoE)
Interventions: budesonide, placebo; Drug
Lead sponsor: Shire; Industry
Eligibility: 2 Years to 18 Years
Enrollment: 82 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 20
States / cities: Phoenix, Arizona • Orange, California • Palo Alto, California + 15 more

Conditions: Smoking Cessation
Interventions: rimonabant; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older
Enrollment: 533 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004
U.S. locations: 1
States / cities: Bridgewater, New Jersey

Conditions: Coronary Heart Disease
Interventions: Placebo, dalcetrapib; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 135 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 10
States / cities: Chicago, Illinois • Indianapolis, Indiana • Iowa City, Iowa + 6 more

Conditions: Rheumatoid Arthritis
Interventions: PDA001, Vehicle Controlled Placebo; Biological · Drug
Lead sponsor: Celularity Incorporated; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 16
States / cities: Anniston, Alabama • Arcadia, California • Los Angeles, California + 12 more

Conditions: Acute Mountain Sickness (AMS)
Interventions: T89 capsule, Placebo capsule; Drug
Lead sponsor: Tasly Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 853 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Risk Reduction
Interventions: Trivalent Salmonella Conjugate Vaccine (TSCV) Full-Strength Formulation, Trivalent Salmonella Conjugate Vaccine (TSCV) Half-Strength Formulation, Trivalent Salmonella Conjugate Vaccine (TSCV) Dilutional Half-Strength Formulation, Placebo; Biological · Other
Lead sponsor: University of Maryland, Baltimore; Other
Eligibility: 18 Years to 49 Years
Enrollment: 82 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Baltimore, Maryland

Search by objective public record fields.

Efficacy and Safety of Losmapimod in Subjects With Facioscapulohumeral Muscular Dystrophy (FSHD)

Sequential Therapy for the Treatment of Severe Bipolar Depression.

Safety and Efficacy Study of Guaifenesin and Pseudoephedrine for Symptomatic Therapy to Treat Acute RTI

Dry Needling and Shoulder Muscle Blood Flow, Motions, and Pain Sensitivity in Individuals with Shoulder Pain

Analgesic Efficacy of Repeated Doses of Intravenous (IV) Acetaminophen in Post-operative Pediatric Spine Fusion Patients

Efficacy and Safety of Empagliflozin (BI 10773) Versus Placebo and Sitagliptin Over 24 Weeks in Patients With Type 2 Diabetes

Clinical and Therapeutic Implications of Fibrosis in Hypertrophic Cardiomyopathy

A Study of Soticlestat as an Add-on Therapy in Children and Young Adults With Dravet Syndrome

Study of NP002 in Subjects With Idiopathic Parkinson's Disease to Treat Dyskinesias Due to Levodopa Therapy

An 8 Week Study Of Depression In Adults Diagnosed With Major Depressive Disorder

A Randomized Controlled Trial Investigating if Antibiotic Use in the First 48 Hours of Life Adversely Impacts the Preterm Infant Microbiome

A Study of Eptinezumab in Pediatric Participants With Episodic Migraine

A Study to Evaluate the Safety and Effectiveness of Ustekinumab or Golimumab Administered Subcutaneously (SC) in Patients With Sarcoidosis

Efficacy, Safety and Pharmacokinetics of Teriflunomide in Pediatric Patients With Relapsing Forms of Multiple Sclerosis

Brexpiprazole as an Adjunctive Treatment to Paroxetine or Sertraline in Adult Patients Suffering From Post-traumatic Stress Disorder (PTSD)

Use of N-Acetylcysteine in the Treatment of Repetitive and Self-Injurious Behaviors in Cornelia de Lange Syndrome

A Study to Evaluate the Efficacy and Safety of Dupilumab in Adult and Adolescent Patients With Moderate-to-Severe Atopic Hand and Foot Dermatitis (Liberty-AD-HAFT)

PROCLAIM: Effect of AC2592 Administered by Continuous Subcutaneous Infusion in Subjects With Advanced Chronic Congestive Heart Failure

Dose-Ranging Study of Oral Viscous Budesonide in Pediatrics With Eosinophilic Esophagitis

Comparison of Efficacy and Safety of Rimonabant 20mg/Day Versus Placebo in Smoking Cessation

A Study of RO4607381 in Patients With Coronary Heart Disease (CHD) or a CHD Risk Equivalent.

Study of Human Placenta-derived Cells (PDA001) to Evaluate the Safety and Effectiveness for Patients With Active Rheumatoid Arthritis

Safety and Efficacy of T89 in the Prevention and Treatment of Adults With Acute Mountain Sickness (AMS)

Salmonella Conjugates CVD 2000: Study of Responses to Vaccination With Trivalent Salmonella Conjugate Vaccine to Prevent Invasive Salmonella Disease